Divers, Jasmin
Mohan, Sumit
Brown, W. Mark
Pastan, Stephen O.
Israni, Ajay K.
Gaston, Robert S.
Bray, Robert
Islam, Shahidul
Sakhovskaya, Natalia V.
Mena-Gutierrez, Alejandra M.
Reeves-Daniel, Amber M.
Julian, Bruce A.
Freedman, Barry I.
Article History
Received: 27 August 2021
Accepted: 1 November 2021
First Online: 3 January 2022
Declarations
:
: This study used data from the SRTR that includes data on all donors, wait-listed candidates, and transplant recipients in the US, submitted by the Organ Procurement and Transplantation Network (OPTN) members. The Health Resources and Services Administration (HRSA) in the US Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. Clinical and research activities are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.The NYU Langone Institutional Review Board granted an exemption from requiring ethics approval on the ground that these analyses are conducted on de-identified data curated by the SRTR. Therefore, written consent was not required for this study based on the granted exemption.
: Not applicable.
: Wake Forest University Health Sciences and Dr. Freedman have rights to an issued United States patent related to <i>APOL1</i> genetic testing. In addition, Dr. Freedman receives research support from and is a consultant for AstraZeneca and RenalytixAI Pharmaceuticals. Dr. Mohan is a member of the Scientific Advisory Board for Angion Biomedica and is the deputy editor for <i>Kidney International Reports</i>. The other authors of this manuscript have no conflict of interest to disclose<i>.</i> Results presented in this paper have not been published previously in whole or part, except in abstract format.